Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 11, 2025 17:09 ET | Source: Bragar Eagel & Squire

TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm

Telix disclosed an SEC subpoena over disclosures on prostate cancer drugs; ADRs fell 10% to $14.58 on July 23, 2025.
September 04, 2025 07:43 ET | Source: Bragar Eagel & Squire

Bragar Eagel & Squire, P.C. Is Investigating Agilon, Albany International, Fluor, and Telix and Encourages Investors to Contact the Firm

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Agilon Health, Inc....
August 23, 2025 09:36 ET | Source: Bragar Eagel & Squire

TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Telix (TLX) To Contact Him Directly To Discuss Their Options If you purchased or acquired...
April 16, 2024 08:30 ET | Source: QSAM Biosciences Inc.

QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER

Austin, TX, April 16, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM) (“QSAM” or the “Company”) previously announced that it will effectuate a reverse stock split of the issued and...
November 14, 2023 07:30 ET | Source: QSAM Biosciences Inc.

QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee

Austin, TX, Nov. 14, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing therapeutic radiopharmaceuticals for the treatment of primary and secondary bone cancer and...
March 21, 2022 18:41 ET | Source: Telix Pharmaceuticals Limited

Telix Radiopharmaceutical Production Facility Buildout Commences

MELBOURNE, Australia and BRUSSELS, Belgium, March 22, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to provide a material update on the development...
March 21, 2022 01:28 ET | Source: Telix Pharmaceuticals Limited

EAU Updates Guidance for PSMA-PET Imaging

MELBOURNE, Australia and LIÈGE, Belgium, March 21, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) welcomes the updated 2022 ‘Guidelines on Prostate...
March 07, 2022 17:37 ET | Source: Telix Pharmaceuticals Limited

ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolment

MELBOURNE, Australia, March 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, “Telix”, the “Company”) today announces that ZIRCON (Zirconium in Renal Cancer Oncology,...
February 15, 2022 17:39 ET | Source: Telix Pharmaceuticals Limited

Telix Enters Commercial Distribution Agreement for Illuccix® in Australia

MELBOURNE, Australia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a commercial distribution agreement with...
February 10, 2022 16:09 ET | Source: Telix Pharmaceuticals Limited

Telix and SHINE partner for Lutetium-177 Supply

MELBOURNE, Australia and INDIANAPOLIS, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a new global clinical supply agreement with...